Indications:
Melanoma
KEYTRUDA is indicated for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC or III melanoma who have undergone complete resection.
*Evaluated as part of Project Orbis
Hepatocellular Carcinoma
KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with an anti-angiogenic tyrosine kinase inhibitor (TKI).
Renal Cell Carcinoma
KEYTRUDA, in combination with lenvatinib, is indicated for the first-line treatment of patients with advanced RCC.
Endometrial Carcinoma
KEYTRUDA, in combination with lenvatinib, is indicated for the treatment of patients with advanced endometrial carcinoma who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.
|